Lestaurtinib

Jump to: navigation, search
220px
Lestaurtinib
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem 126565
Chemical data
Formula C26H21N3O4 
Mol. mass 439.462 g/mol
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

WikiDoc Resources for Lestaurtinib

Articles

Most recent articles on Lestaurtinib

Most cited articles on Lestaurtinib

Review articles on Lestaurtinib

Articles on Lestaurtinib in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lestaurtinib

Images of Lestaurtinib

Photos of Lestaurtinib

Podcasts & MP3s on Lestaurtinib

Videos on Lestaurtinib

Evidence Based Medicine

Cochrane Collaboration on Lestaurtinib

Bandolier on Lestaurtinib

TRIP on Lestaurtinib

Clinical Trials

Ongoing Trials on Lestaurtinib at Clinical Trials.gov

Trial results on Lestaurtinib

Clinical Trials on Lestaurtinib at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lestaurtinib

NICE Guidance on Lestaurtinib

NHS PRODIGY Guidance

FDA on Lestaurtinib

CDC on Lestaurtinib

Books

Books on Lestaurtinib

News

Lestaurtinib in the news

Be alerted to news on Lestaurtinib

News trends on Lestaurtinib

Commentary

Blogs on Lestaurtinib

Definitions

Definitions of Lestaurtinib

Patient Resources / Community

Patient resources on Lestaurtinib

Discussion groups on Lestaurtinib

Patient Handouts on Lestaurtinib

Directions to Hospitals Treating Lestaurtinib

Risk calculators and risk factors for Lestaurtinib

Healthcare Provider Resources

Symptoms of Lestaurtinib

Causes & Risk Factors for Lestaurtinib

Diagnostic studies for Lestaurtinib

Treatment of Lestaurtinib

Continuing Medical Education (CME)

CME Programs on Lestaurtinib

International

Lestaurtinib en Espanol

Lestaurtinib en Francais

Business

Lestaurtinib in the Marketplace

Patents on Lestaurtinib

Experimental / Informatics

List of terms related to Lestaurtinib


Overview

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders. It is an analog of staurosporine.

As of 2008, it is currently in Phase III clinical trials for AML and Phase II clinical trials for myeloproliferative disorders. [1]

It is being developed by Cephalon.

References



Linked-in.jpg